Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.

@article{Duinkerke1993RitanserinAS,
  title={Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.},
  author={S J Duinkerke and P A Botter and Annemarie L M A Jansen and P A van Dongen and A J van Haaften and A. J. W. van den Boom and J H van Laarhoven and H. L. S. M. Busard},
  journal={The British journal of psychiatry : the journal of mental science},
  year={1993},
  volume={163},
  pages={
          451-5
        }
}
The effectiveness of ritanserin, a selective 5-HT2 and 5-HT1c antagonist, in reducing negative symptoms in schizophrenia was investigated in a double-blind, placebo-controlled trial. Trial treatment was added to a stable neuroleptic treatment in 33 schizophrenic patients with predominantly negative symptoms. Ritanserin reduced the negative symptoms, as… CONTINUE READING